Effectiveness and safety of inactivated SARS-CoV2 vaccine (BBIBP-CorV) among healthcare workers: A seven-month follow-up study at fifteen hospitals

Abstract

OBJECTIVE Health care workers_ the first line army in the current pandemic_ are the most vulnerable group for COVID-19 infection. Vaccination of health care workers is strongly recommended to salvage our army. However, more research is needed to determine the safest and most effective vaccine. In our study, we assessed the safety and effectiveness of the first approved vaccine in Egypt_ the Sinopharm vaccine. DESIGN, SETTING: An ambispective cohort study was conducted in fifteen triage and isolation hospitals, from the 1st of March till the end of September 2021. Participants are either fully vaccinated or unvaccinated. OUTCOMES AND MEASURES: Efficacy outcome to assess vaccine effectiveness, severity outcome to assess incidence rate of hospitalized cases (severe to critically ill) or the COVID-19 related mortality, in addition to the safety of the vaccine. INTERPRETATION: From the selected hospitals, we included 1228 of 1364 interviewed healthcare workers. Vaccine effectiveness was 67% to protect against symptomatic PCR confirmed cases and 46% for total COVID-19 infection after adjusting hazard ratio. Incidence rate ratios of vaccinated to unvaccinated group were 0.39 (95%CI, 0.24–0.65) for PCR confirmed symptomatic case, 0.63 (95%CI, 0.46–0.86) for total COVID-19 infection, 0.45 (95% CI, 0.15–1.31) for hospitalization, 0.71 (95% CI, 0.07– 6.39) for mechanical ventilation and only one COVID-19 death among unvaccinated group. Most adverse events are mild and well-tolerated. Pregnant and lactating vaccinated mothers did not report any sentinel adverse events. CONCLUSION Sinopharm was effective in protecting health care workers from the highly transmissible COVID-19 infection when the predominant Delta variant was ambient.

Primary Series COVID-19 Vaccine Effectiveness among Health Care Workers in the Country of Georgia, March–December 2021

“…6 Our study is one of few studies globally to evaluate VE of primary series BBIBP-CorV against symptomatic infection during the Delta period [6]. Our finding of 40% VE was in the range of primary series BBIBP-CorV VE against symptomatic infection during Delta described in two studies from China, which found aVE of 50% (95%CI: 4; -74) [18] and 75 (95%CI: 6; -94) [19], and one study from Egypt, that found VE of 67% (95%CI: 43; 80) [20]. Studies of BBIBP-CoRV against more severe outcomes have shown mixed results, but have consistently shown the added benefit of booster doses, mostly against Delta but also against Omicron; a study of primary series BBIBP-CorV VE against hospitalization among people aged 18-64 years old in Hungary during Delta found a VE of 54% (44; 62) in the 14-120 days following the second dose that decreased over time, but increased to 77-95% following homologous or heterologous booster [21]; for 65-100 year-olds, the same study found slightly lower VE against hospitalization with similar trends following booster doses.…”

Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population

“…An ambispective cohort study assessing VE of BBIBP-CorV (Sinopharm) against COVID-19-related ICU admission among healthcare workers across Egypt, and a study from Hungary (HUN-VE 3) estimating effectiveness of six different vaccine types, including BBIBP-CorV (Sinopharm) and ChAdOx1 nCoV-2 against COVID-19-related hospitalisation and death, both reported more modest BBIBP-CorV (Sinopharm) VE estimates during a period of delta variant transmission, compared to other studies [15][16][17][18][19][20]. These were reported as an overall adjusted VE of 65% and 45.7% against hospitalisation in studies from Egypt and Hungary, respectively, and 58.6% against COVID-19-related death in the study from Hungary [15,21]. To our knowledge, our study is the third to report on BBIBP-CorV (Sinopharm) effectiveness data within the context of a delta variant…”

Immunogenicity of the BBIBP-CorV Vaccine; An Observational Study from Pakistan

“…and 100% effective in preventing moderate and severe disease. 21 Vaccination efforts currently underway all over the world are the most important weapon in our arsenal against the COVID-19 pandemic. A number of different vaccines have been developed in different areas of the world.…”